摩根士丹利发首次覆盖研报指,维升药业(2561.HK)(“维升”)是专注于内分泌治疗的强劲增长型企业,其独特的起源背景使其能够加速推进已在海外验证的产品管线,从而在无需承担传统引进许可成本的前提下,捕捉中国代谢类疾病市场的显著增长潜力。 维升正在开发的三项源自Ascendis的产品,这些产品均基于TransCon技术平台。TransCon平台赋予了传统需每日使用的激素疗法以长效注射的潜力,使药物的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.